PTC Therapeutics, Inc.
PosiFunda Ratios Only on PositoAI
PositoAI's own ratios from PTC Therapeutics, Inc.'s yearly results (2022–2025), compared with Healthcare companies in United States. Tap ? on any ratio for what it means.
Where $100 of sales goes
Latest year (Dec 2025). Taxes and other income are not shown, so the parts need not add up to 100.
Cash quality
Profit Cash Ratio
—Loss-making or profit too small
Over the last 3 years profit was a loss or under 2% of sales, so cash per 100 of profit is not meaningful.
Self-Funding Ratio
0.9×Over the last 3 years its own operating cash paid for 90% of its investment spending (capex); the rest came from other sources such as borrowing, cash reserves or new shares.
Higher than 68% of Healthcare companies in United States.
Cash Locked Ratio
$12For every $100 of sales, $12 is tied up in day-to-day operations (money owed by customers + stock − money owed to suppliers), against $21 tied up three years earlier.
Less money tied up than 75% of Healthcare companies in United States.
Growth quality
Steadiness Ratio
2/3 · 2/3Sales grew in 2 of the last 3 years; profit grew in 2 of 3.
Steadier than 69% of Healthcare companies in United States.
Growth Efficiency Ratio
$120Sales grew 148% in 3 years; of every extra $100 of sales, $120 became extra profit.
Higher than 83% of Healthcare companies in United States.
Asset Productivity Ratio
+148% / +70%In 3 years sales changed by +148% while total assets changed by +70%. Sales grew faster than assets.
Balance-sheet strength
Debt Due Cover Ratio
1.2×Debt due within a year is covered 1.2 times by its yearly operating cash.
Higher than 72% of Healthcare companies in United States.
Cash Cushion Ratio
−14%Debt, after subtracting cash, equals 14% of its market value (net debt).
Lower than 81% of Healthcare companies in United States.
Tangible Assets Ratio
84%Of every $100 the company owns, $84 is in tangible assets such as plants, cash, stock and receivables; the rest is goodwill and other intangibles.
More tangible than 54% of Healthcare companies in United States.
Tangible Net Worth Ratio
—Data incomplete
Shareholders
Standard fundamentals
P/E, P/B, ROE, debt, growth and more (12)
PTC Therapeutics, Inc. made a loss over the last year. PTC Therapeutics, Inc. owes $1.05 for every $1 it owns. PTC Therapeutics, Inc. returned to profit in the year to Dec 2025, after a loss the year before.
Compared with Healthcare companies in United States · latest annual results Dec 2025.
P/E ratio
LossPTC Therapeutics, Inc. made a loss over the last year, so its P/E ratio is not meaningful.
P/B ratio
-31.82PTC Therapeutics, Inc.'s book value is negative (it owes more than it owns), so P/B is not meaningful.
Market cap
$5.3 BThe total market value of all of PTC Therapeutics, Inc.'s shares at today's price (share price × number of shares), larger than 85% of Healthcare companies in United States. PosiCap size class: Meso Cap.
Net worth (book value)
NegativePTC Therapeutics, Inc.'s net worth is negative ($165 M below zero, balance sheet 30 Jun 2026): it owes more than it owns, so book value per share and P/B are not meaningful.
Owes vs Owns
1.05×PTC Therapeutics, Inc. owes $1.05 for every $1 it owns, so it owes more than it owns, higher than 89% of Healthcare companies in United States.
Dividend yield
NonePTC Therapeutics, Inc. does not currently pay a dividend.
Revenue growth
+115%Revenue rose 115% in the year to Dec 2025, and grew 35% a year on average over 3 years.
Profit growth
Back to profitPTC Therapeutics, Inc. returned to profit in the year to Dec 2025, after a loss the year before.
Profit margin
39.4%PTC Therapeutics, Inc. keeps $39 of every $100 of revenue as net profit.
Cash quality
1.04×Cash from PTC Therapeutics, Inc.'s business was 1.04× its reported profit in the year to Dec 2025 — its profit turned into cash.
Interest cover
5.6×PTC Therapeutics, Inc.'s operating profit covered its interest costs 5.6 times in the year to Dec 2025.
Cash vs debt
Net debtPTC Therapeutics, Inc. had $762 M more debt than cash (net debt) at Dec 2025.
Questions
How much does PTC Therapeutics, Inc. owe compared with what it owns?
PTC Therapeutics, Inc. owes $1.05 for every $1 it owns, so it owes more than it owns, higher than 89% of Healthcare companies in United States.
Does PTC Therapeutics, Inc. pay a dividend?
No. PTC Therapeutics, Inc. does not currently pay a dividend.
Is PTC Therapeutics, Inc.'s revenue growing?
Revenue rose 115% in the year to Dec 2025, and grew 35% a year on average over 3 years.
Figures from the company's yearly results and PositoAI's own data. Full tables are on the Go Deep tab. What each figure means. PositoAI is for research and education only and is not investment advice.